uniQure (NASDAQ:QURE) Price Target Raised to $31.00

uniQure (NASDAQ:QURE) had its price target raised by Chardan Capital from $16.00 to $31.00 in a research report sent to investors on Monday, MarketBeat.com reports. Chardan Capital currently has a buy rating on the biotechnology company’s stock.

QURE has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of uniQure in a report on Tuesday, February 10th. Leerink Partners restated an “outperform” rating and issued a $35.00 price target on shares of uniQure in a research note on Monday, March 2nd. Sanford C. Bernstein lowered uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Royal Bank Of Canada upgraded uniQure from a “sector perform” rating to an “outperform” rating and increased their price objective for the company from $11.00 to $35.00 in a research note on Monday. Finally, The Goldman Sachs Group decreased their target price on uniQure from $37.00 to $9.00 and set a “neutral” rating for the company in a report on Tuesday, March 3rd. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.25.

uniQure Stock Down 3.8%

Shares of NASDAQ:QURE opened at $17.56 on Monday. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43. The firm has a market capitalization of $1.10 billion, a PE ratio of -5.09 and a beta of 0.73. The firm’s 50-day moving average is $21.67 and its two-hundred day moving average is $29.58. uniQure has a 1 year low of $7.76 and a 1 year high of $71.50.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.93) by $0.37. The business had revenue of $5.57 million during the quarter, compared to analyst estimates of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. Analysts predict that uniQure will post -3.75 EPS for the current year.

Insider Buying and Selling

In other news, Director Jack Kaye sold 6,390 shares of the stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the transaction, the director owned 20,439 shares in the company, valued at approximately $557,575.92. This represents a 23.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Christian Klemt sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $108,720.00. Following the sale, the chief financial officer owned 226,581 shares of the company’s stock, valued at approximately $2,052,823.86. The trade was a 5.03% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 81,399 shares of company stock worth $1,527,645. Corporate insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

Several institutional investors have recently modified their holdings of QURE. Swiss National Bank purchased a new stake in shares of uniQure in the 2nd quarter valued at about $1,080,000. Sanders Morris Harris LLC acquired a new stake in shares of uniQure in the 3rd quarter valued at about $5,081,000. Vanguard Group Inc. grew its stake in uniQure by 15.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock worth $65,673,000 after buying an additional 152,417 shares during the last quarter. Aberdeen Group plc increased its position in uniQure by 6.9% during the third quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock worth $171,593,000 after buying an additional 189,029 shares during the period. Finally, JPMorgan Chase & Co. increased its position in uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after buying an additional 1,491,486 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Several analyst upgrades and bullish reports have pushed optimism around the company’s pipeline — Mizuho upgraded QURE to “outperform” with a $35 target (up from $12), and other firms (RBC, Wells Fargo, Chardan) have issued more favorable notes recently, supporting a rebound narrative for the stock. Mizuho Upgrade
• Positive Sentiment: H.C. Wainwright reaffirmed a Buy rating and kept a $70 price target, citing regulatory shifts and AMT‑130 outlook as catalysts that could drive long-term upside. H.C. Wainwright Note
• Neutral Sentiment: Shares previously spiked (~26% reported) on an FDA leadership shakeup that some investors hoped would favor uniQure’s Huntington’s therapy pathway — a short-term momentum event that may have already priced in expectations. MSN Coverage
• Negative Sentiment: Regulatory risk intensified after reports that the FDA publicly rebuked uniQure, alleging the company pushed “distorted” or “manipulated” data around the failed AMT‑130 program — a serious development that raises oversight, approval, and credibility concerns. FDA Allegation Report
• Negative Sentiment: Multiple plaintiff firms have filed or are soliciting investors for securities‑fraud class actions tied to uniQure’s FDA delays and share decline, creating legal overhang, potential liabilities, and continued headline risk that can pressure the stock. Kessler Topaz Filing
• Negative Sentiment: Short interest jumped significantly in February (over 17% increase), now representing ~21% of float — a condition that can amplify downside on negative news and reflects elevated bearish positioning.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.